Skip to main content
Fig. 2 | Journal of Inflammation

Fig. 2

From: The synthetic cannabinoid WIN55,212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB2, TRPV1, TRPA1 and yet unidentified receptor targets

Fig. 2

Influence of high concentrations of WIN55212-2 mesylate (WIN, 10−6M to 10−5M) with and without antagonists on TNF-induced IL-6 (a), IL-8 (b) and MMP-3 (c) production in RA and OA synovial fibroblasts. Cytokine/MMP-3 production was determined under hypoxic (1 % O2) conditions. ***p < 0.001 for comparisons vs control (TNF only, 100 %, dotted line). ###p < 0.001, ##p < 0.01, #p < 0.05 for comparisons vs WIN/TNF only w/o antagonists. The general linear model with Bonferroni correction was used for all comparisons. All data are given as mean ± sem. Calcium chelator = BAPTA-Am, TRPV1 antagonist = capsazepine, TRPA1 antagonist = A967079, AMPK activator = metformin

Back to article page